ASCO 2017: The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer

Chicago, IL (UroToday.com) Dr. Tandstad and colleagues presented their study design of the ABC study, a randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin among patients with stage I seminoma testicular cancer, at today’s ASCO 2017 annual meeting.

ASCO 2017: Taking Us Out of the Refractory State: Combination Chemotherapy to Immunotherapy for Refractory Germ Cell Tumors

Chicago, IL (UroToday.com) Dr. Gillessen from Switzerland provided a very thorough and excellent discussion of three testicular cancer abstracts presented at the 2017 ASCO annual meeting. The abstracts she discussed were Abstract 4519 (Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) +/- bevacizumab as an effective high-dose chemotherapy (HDC) regimen for refractory of poor risk relapsed germ-cell tumors [1]), 4520 (Phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors [2]), and 4521 (FDG PET scan positive residual lesions after chemotherapy for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry [3]).

ASCO 2017: Long-term causes of relative excess mortality after diagnosis of testicular germ cell tumor

Chicago, IL (UroToday.com) Testicular germ cell tumors (TGCT) have excellent cure rates nowadays. However, there is a reduced long-term relative survival (RS) which is an increasing concern. A recent study showed a continuing decline in RS among these patients diagnosed in Norway, even after more than 30 years of follow-up.1

ASCO 2017: Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer

Chicago, IL (UroToday.com) It is known that testicular cancer (TC) survivors are at risk to develop early cardiovascular morbidity. Close collaboration between oncologists and primary care physicians (PCPs) is mandatory for optimal cardiovascular risk management.

ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry

Chicago, IL (UroToday.com) Residual disease is a frequent finding after chemotherapy for metastatic testicular seminoma, seen in 55-80% of patients. Watchful waiting is recommended for residual lesions < 3 cm or lesions ≥3 cm with negative FDG-PET scan. In seminoma postchemotherapy residual masses of up to 3 cm represent necrosis in 97-100% and FDG-PET is not recommended.

ASCO 2017: Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT)

Chicago, IL (UroToday.com) While patients with testicular cancer often have very high cure rates in the cisplatin era, even in the setting of relapsed disease, many can often be salvaged with standard-dose (SDCT) or high-dose chemotherapy (HDCT). However, up to 15% of patients with relapsed GCT are not curable, and it is in these patients that novel HDC regimens or alternative regimens are needed.

ASCO 2017: Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT)

Chicago, IL (UroToday.com) While patients with testicular cancer often have very high cure rates in the cisplatin era, a small population of patients who have poor-risk germ cell tumors (GCT) and relapse despite initial chemotherapy or are refractory to initial treatment regimens have poor prognosis.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe